CORDIS
EU research results

CORDIS

English EN
Preclinical Intra-Operative Image-Guided Surgery and Post-Operative Radiotherapy of Tumours

Preclinical Intra-Operative Image-Guided Surgery and Post-Operative Radiotherapy of Tumours

Objective

The main objective and basic concept of our proposal is to improve intra-operative and post-operative targeted surgical probes and new detection systems for surgical intervention of cancer. The work revolves around the mobility of clinicians, scientists and technologists between twelve consortium partners and across four different countries. The goal is the implementation of inter-disciplinary, inter-sector, cross-training of personnel. As a consequence, this will serve to accelerate the development of improved imaging technologies and hybrid fluorescence/radionuclide probes for the surgical intervention of cancer. The hypothesis is that if we can develop a hybrid probe for both targeted image-guided surgery and post-operative molecular radiotherapy, we would be implementing a revolutionary imaging and therapeutic approach for oncology surgeons to help their patients by improving better overall survival and quality of life for the patient. There are four key objectives within this project: 1) synthesis of a near infra-red fluorescence (NIRF)-dye conjugated to a peptide that is targeted towards a tumour associated antigen, 2) deliver a novel clinical optoacoustic handheld camera to detect the fluorescence probe in deep tissue, 3) validate the probe/target combination across the subcellular, cellular, endoscopic and macroscopic levels with state-of-art technologies, and 4) develop the probe further by targeting a radionuclide entity to the fluorescent construct for postoperative radiotherapy. Surgeons would have a more definitive reference for resection, if the tumour margin can be clearly defined. If this can be achieved, the impact would be (a) reduced recurrence rates in patients by lowering the risk of residual tumour tissue remaining after surgery and as a consequence improve survival, (b) minimised removal of healthy tissues, c) reduced patient morbidity and hospital stay and d) significant health cost benefits.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

PERCUROS BV

Address

Plesmanlaan 1
2333 Bz Leiden

Netherlands

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 378 000

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 486 000

UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS

Germany

EU Contribution

€ 243 000

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 162 000

ITHERA MEDICAL GMBH

Germany

EU Contribution

€ 54 000

TAGWORKS PHARMACEUTICALS BV

Netherlands

EU Contribution

€ 108 000

RAYFOS LTD

United Kingdom

EU Contribution

€ 216 000

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 189 000

MAUNA KEA TECHNOLOGIES

France

EU Contribution

€ 108 000

GAMMA TECHNOLOGIES LIMITED

United Kingdom

EU Contribution

€ 162 000

ANTIBODIES FOR RESEARCH APPLICATIONS BV

Netherlands

EU Contribution

€ 54 000

TECOBIOSCIENCES GMBH

Germany

EU Contribution

€ 108 000

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 54 000

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 108 000

Project information

Grant agreement ID: 644373

Status

Closed project

  • Start date

    1 February 2015

  • End date

    31 January 2019

Funded under:

H2020-EU.1.3.3.

  • Overall budget:

    € 2 430 000

  • EU contribution

    € 2 430 000

Coordinated by:

PERCUROS BV

Netherlands